Mylan to buy MS drug marketing rights from Mapi Pharma
Mylan NV will buy global marketing rights to an experimental multiple sclerosis treatment from Israel’s Mapi Pharma, aiming to strengthen its position in the market for MS drugs and counter falling sales of its emergency allergy shot EpiPen.
Mylan already sells a generic version of Teva Pharmaceutical Industries Ltd’s blockbuster MS treatment Copaxone.
Mapi has tested the drug in a mid-stage study and is preparing for a late-stage trial to support marketing applications to global health regulators, including the U.S. Food and Drug Administration.
The companies also said Mylan would invest in Mapi but did not disclose financial details.
According to Israeli news website Haaretz.com here, Mylan is expected to invest a $20 million private placement in Mapi.
Both companies did not immediately respond to a request for comment.
Nearly 1 million people in the United States suffer from multiple sclerosis, a lifelong disease that affects the brain and spinal cord.
(Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila and Saumyadeb Chakrabarty)
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd